Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Year: 2025
Type: other
Abstract: Cell-surface target expression is variable across CTC phenotypes. A, Heatmap of gene expression of cell-surface targets ordered by clustering in Fig. 1D. B–J, Cell-surface target expression by CTC phenotype for targets associated with prostate adenocarcinoma (KLK2, STEAP1, and STEAP2), pan-cancer cell-surface targets expressed in prostate cancer including TACSTD2 (TROP2), ERBB2 (HER2), and tumor immune checkpoint cell-surface protein CD276 (B7H3), as well as targets associated with prostate neuroendocrine differentiation (DLL3, CEACAM5, and SSTR2). For patients with multiple CTC samples, the highest purity sample is included (Low_CTC, n = 30; Low_prolif, n = 12; LumA, n = 24; LumB, n = 31; and NE, n = 3). Low_CTC samples are included for reference but not included in statistical comparisons because they are expected to have low/no expression due to low CTC content.
Authors: Marina N. Sharifi, Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, Viridiana Carreno, Katherine R. Kaufmann, Alex H. Chang, Luke A. Nunamaker, Charlotte Linebarger, Leilani Mora-Rodriguez, Jennifer L. Schehr, Hannah M. Krause, Kyle T. Helzer, Matthew L. Bootsma, Grace C. Blitzer, John M. Floberg, Christos E. Kyriakopoulos, Hamid Emamekhoo, Elisabeth I. Heath, Meghan Wells, Scott T. Tagawa, Martin Sjöström, Atish D. Choudhury, Menggang Yu, Andrew J. Armstrong, Dana E. Rathkopf, Himisha Beltran, Peter S. Nelson, Felix Y. Feng, Scott M. Dehm, David Kosoff, Xiao X. Wei, Rana R. McKay, Shuang G. Zhao, Joshua M. Lang
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4410047378